Kringle Pharma and Maruho Agreed to Conclude an Option Agreement for ChronSeal®

Kringle Pharma, Inc. (Head office located in Toyonaka, Osaka; President & CEO: Kunio Iwatani, “KRINGLE”) proudly announces that it has reached to a basic agreement with Maruho Co., Ltd. (Head office located in Osaka; President & CEO: Koichi Takagi, “MARUHO”) to enter into an option agreement for ChronSeal®. A multi-center phase I/II clinical trial of ChronSeal® is currently underway for the subjects with venous leg ulcers in Norway and Sweden (refer to our press releases dated 3 December 2008 and 28 January 2009).

ChronSeal® is a topical application therapy having recombinant human hepatocyte growth factor (HGF) as a main active pharmaceutical ingredient. KRINGLE and MARUHO has agreed that upon concluding an option agreement, KRINGLE will grant MARUHO the following rights in the territory of Japan. In return, KRINGLE will receive a certain option fee.

1) The first review right for evaluating the clinical results from the phase I/II clinical trial of ChronSeal®
2) The first negotiation right for the licensing of exclusive development and marketing of ChronSeal®

“I am extremely proud that KRINGLE reached to a basic agreement with MARUHO, the Japan’s leading specialty pharmaceutical company in the field of dermatology, to conclude an option agreement for ChronSeal®. Last December, KRINGLE established Kringle Pharma Europe AB (“Kringle Europe”) in Sweden to accelerate the clinical development of ChronSeal® in Scandinavian countries (refer to our press release dated 17 December 2008). We will push forward the clinical development of ChronSeal® through the operation of Kringle Europe to achieve proof of concept (POC) of HGF as pharmaceutical product.” said Kunio Iwatani.

About Kringle Pharma, Inc.
Kringle Pharma is a biopharmaceutical company established in 2001 to develop novel biologics based on HGF and NK4, both discovered by Professor Emeritus Toshikazu Nakamura at Osaka University. Currently, Kringle’s pipeline consists of recombinant human HGF for the treatment of 1) acute renal failure, 2) skin ulcers, and 3) CNS diseases, in addition to recombinant human NK4 and NK4 gene drugs for cancer therapy. For more information, please refer to the company’s website: www.kringle-pharma.com/en/index.html.

About Maruho Co., Ltd.
Maruho is a specialty pharmaceutical company focusing on research, development, manufacturing and sales of pharmaceuticals for medical use, mainly in the field of dermatology. Maruho’s drug-development and pharmaceutical technology has been cultivated over more than 90 years. Its mission is to seek out and find solutions that enable to make a high-quality contribution to the health of mankind.

Address: Kita-ku, Osaka, Japan
President & CEO: Koichi Takagi
Sales: 47,690 million yen (FY 2008)
Company’s website: www.maruho.co.jp/english/index.html

For more information, please contact:
Tomoya Shimojo, Director of Corporate Planning & CFO, Kringle Pharma, Inc.
Tel: +81 6 6831 3330
E-mail: info@kringle-pharma.com